Pharmacologic Treatment of Attention-Deficit/Hyperactivity Disorder: Efficacy, Safety and Mechanisms of Action
The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.
Abstract
Studies examining the efficacy, safety and mechanisms of action of agents for the treatment of attention-deficit/hyperactivity disorder (ADHD) are reviewed, with an emphasis on newer agents such as the long acting stimulants and atomoxetine. Recent studies of medications are characterized by large, rigorously diagnosed samples of children, adolescents and adults with ADHD, use of standardized rating scales and extensive safety data. These studies confirm a robust treatment effect for the Food and Drug Administration approved agents ranging from 0.7 to 1.5. The most common short term side effects to the most commonly used agents include insomnia, loss of appetite, and headaches. Despite public controversy and labeling changes to warn of extremely rare cardiovascular and psychiatric side effects, the evidence does not support the hypothesis that medication for ADHD increases risk for sudden death, mania or psychosis. A wide variety of neuroimaging techniques including electrocephalogram (EEG) power, event related potentials (ERP), functional magnetic resonance imaging (fMRI), and positron emission tomography (PET) are beginning to examine the mechanisms of action of medications for ADHD, and implicating the catecholamines and prefrontal and anterior cingulate cortices as prime sites of actions for these agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“evidence from a large body of studies showed that treatment responses from different patients are widely different in terms of the types of pharmacological treatments, dosage requirements, tolerability, response rates, and adverse-event profiles (Spencer et al., 1996; Efron et al., 1997; Pliszka, 2007; Newcorn et al., 2008; Victor et al., 2009; Wilens et al., 2011; Hodgkins et al., 2012).”
From A Review of Heterogeneity in Attention Deficit/Hyperactivity Disorder (ADHD) (2019) · cites this paper as Pliszka, 2007
In the citing paper
“pharmacological treatment has limitations including unfavorable side effects for some patients [8]”
From Proof-of-concept study of an at-home, engaging, digital intervention for pediatric ADHD (2018) · cites this paper as [8]
Citations
Cites
ADHD and The Nature of Self-Control
Barkley, R. A., & Wasserstein, J. (2000) · Journal of Cognitive Psychotherapy · doi:10.1891/0889-8391.14.1.111 · Cited by 1,513
ADHD and the Nature of Self-Control
Hinshaw, S. P. (1998) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/00004703-199806000-00010 · Cited by 1,194
Suicidality in Pediatric Patients Treated With Antidepressant Drugs
Hammad, T. A., Laughren, T., & Racoosin, J. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.332 · Cited by 1,054
THE BEHAVIOR OF CHILDREN RECEIVING BENZEDRINE
Bradley, C. (1937) · American Journal of Psychiatry · doi:10.1176/ajp.94.3.577 · Cited by 1,035
Volkow, N. D., Wang, G.-J., Fowler, J. S., Gatley, S. J., Logan, J., Ding, Y.-S., Hitzemann, R., & Pappas, N. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.10.1325 · Cited by 885 · cited 2×
“transporters in the striatum (Volkow et al., 1998).”
BackgroundInfluentialBush, G., Frazier, J. A., Rauch, S. L., Seidman, L. J., Whalen, P. J., Jenike, M. A., Rosen, B. R., & Biederman, J. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00083-9 · Cited by 866 · cited 2×
“…comparisons of ADHD children to controls during fMRI have shown differences in fronto-striatal activity (Bush, Valera, & Seidman, 2005), particularly in the right prefrontal cortex (Rubia, Smith, Brammer, Toone, & Taylor, 2005) and anterior cingulate (Bush et al., 1999; Pliszka et al., 2006b).”
BackgroundVaidya, C. J., Austin, G., Kirkorian, G., Ridlehuber, H. W., Desmond, J. E., Glover, G. H., & Gabrieli, J. D. E. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.24.14494 · Cited by 845 · cited 1×
“Initially, Vaidya et al. (1998) showed that MPH, relative to placebo, increased frontal activation in both children with ADHD and controls.”
BackgroundPharmacotherapy of Attention-Deficit Hyperactivity Disorder across the Life Cycle
SPENCER, T., BIEDERMAN, J., WILENS, T., HARDING, M., O'DONNELL, D., & GRIFFIN, S. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199604000-00008 · Cited by 830 · cited 2×
“were found in 161 studies encompassing 5 preschool, 140 school age, 7 adolescent and 9 adult RCTs (Spencer et al., 1996).”
BackgroundBarry, R. J., Clarke, A. R., & Johnstone, S. J. (2003) · Clinical Neurophysiology · doi:10.1016/s1388-2457(02)00362-0 · Cited by 819 · cited 1×
“Healthy controls produce a larger P300 wave to the oddball tones than to the common tones, but this difference is markedly reduced in children with ADHD (Barry et al., 2003).”
BackgroundAtomoxetine in adults with ADHD: two randomized, placebo-controlled studies
Michelson, D., Adler, L., Spencer, T., Reimherr, F. W., West, S. A., Allen, A. J., Kelsey, D., Wernicke, J., Dietrich, A., & Milton, D. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01671-2 · Cited by 790 · cited 7×
“Thus it is tempting to conclude that MPH increases the allocation of mental resources to a task, but Springer further studies have not borne this out.”
BackgroundInfluential
Cited by
Neurocognitive Effects of Methamphetamine: A Critical Review and Meta-analysis
Scott, J. C., Woods, S. P., Matt, G. E., Meyer, R. A., Heaton, R. K., Atkinson, J. H., & Grant, I. (2007) · Neuropsychology Review · doi:10.1007/s11065-007-9031-0 · Cited by 671
“Moreover, current pharmacologic treatments for ADHD (e.g., methylphenidate) target dopaminergic systems, and, similar to MA, operate by blocking reuptake of dopamine and norepinephrine (Pliszka 2007).”
BackgroundSharma, A., & Couture, J. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028013510699 · Cited by 516
“Comorbidities such as ODD, MDD, and anxiety disorders create more difficulties for ADHD diagnosis because of the similarities of these disorders with symptoms and characteristics of ADHD.”
BackgroundInfluentialA Review of Heterogeneity in Attention Deficit/Hyperactivity Disorder (ADHD)
Luo, Y., Weibman, D., Halperin, J. M., & Li, X. (2019) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2019.00042 · Cited by 394
“Although different pharmacological treatment strategies have been applied to ADHD patients with various comorbidities, evidence from a large body of studies showed that treatment responses from different patients are widely different in terms of the types of pharmacological treatments, dosage requirements, tolerabilit…”
BackgroundAttention-Deficit/Hyperactivity Disorder and Attention Networks
Bush, G. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.120 · Cited by 358
“Pliszka SR (2007). Pharmacologic treatment of attention-deficit/hyperactivity”
BackgroundInfluentialAdvokat, C. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.03.006 · Cited by 219
Advokat, C., Lane, S. M., & Luo, C. (2011) · Journal of Attention Disorders · doi:10.1177/1087054710371168 · Cited by 201
“…increased the pharmacological treatment of adults with ADHD (Davidson, 2008; Dodson, 2005; Dopheide & Plizka, 2009 Faraone, Spencer, Aleardi, Pagano, & Biederman, 2004; Pliszka, 2007; Robison, Sclar, & Skaer, 2005), particularly in undergraduate populations (see Wilens et al., 2008, for review).”
BackgroundCognition enhancers between treating and doping the mind
Lanni, C., Lenzken, S. C., Pascale, A., Del Vecchio, I., Racchi, M., Pistoia, F., & Govoni, S. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.02.004 · Cited by 166
“[56] Pliszka SR.”
BackgroundTreatment of adults with attention-deficit/hyperactivity disorder
Hechtman, L. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s6985 · Cited by 157
Kim, J., Mutyala, B., Agiovlasitis, S., & Fernhall, B. (2011) · Preventive Medicine · doi:10.1016/j.ypmed.2011.01.003 · Cited by 169
Martínez-Raga, J., Knecht, C., Szerman, N., & Martínez, M. (2012) · CNS Drugs · doi:10.1007/s40263-012-0019-9 · Cited by 147
“Despite existing controversy, the risk for serious cardiovascular adverse events and sudden cardiac death associated with stimulants, atomoxetine or a2-adrenergic agonists prescribed for ADHD is extremely low and the benefits of treating individual patients with ADHD, after an adequate assessment, outweigh the risks […”
BackgroundAssessment of Attention in Preschoolers
Mahone, E. M., & Schneider, H. E. (2012) · Neuropsychology Review · doi:10.1007/s11065-012-9217-y · Cited by 123
“The presumed mechanism of action of stimulants, which has been established via studies of older children and adults (but not among preschoolers), is by increasing the availability of catecholamines (especially dopamine and norepinephrine) in the synaptic cleft (Pliszka 2007).”
BackgroundHalbauer, J. D., Ashford, J. W., Zeitzer, J. M., Adamson, M. M., Lew, H. L., & Yesavage, J. A. (2009) · The Journal of Rehabilitation Research and Development · doi:10.1682/jrrd.2008.08.0119 · Cited by 143
“0, one of the largest effect sizes of any psychotropic medication [102].”
BackgroundAerobic Exercise and Attention Deficit Hyperactivity Disorder: Brain Research
CHOI, J. W., HAN, D. H., KANG, K. D., JUNG, H. Y., & RENSHAW, P. F. (2015) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000000373 · Cited by 118
“In addition, treated individuals may experience short-term side effects, including insomnia, loss of appetite, and headaches, and rare side effects including mania, psychosis, and increased risk of sudden death (27).”
BackgroundProof-of-concept study of an at-home, engaging, digital intervention for pediatric ADHD
Davis, N. O., Bower, J., & Kollins, S. H. (2018) · PLOS ONE · doi:10.1371/journal.pone.0189749 · Cited by 106
Psychosocial Treatments for Children with Attention Deficit/Hyperactivity Disorder
Daly, B. P., Creed, T. A., Xanthopoulos, M. S., & Brown, R. T. (2007) · Neuropsychology Review · doi:10.1007/s11065-006-9018-2 · Cited by 147
Neurofeedback in children with ADHD: validation and challenges
Gevensleben, H., Rothenberger, A., Moll, G. H., & Heinrich, H. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.22 · Cited by 105
Neurofeedback and Neuromodulation Techniques and Applications
Coben, R., & Evans, J. R. (2011) · Elsevier eBooks · doi:10.1016/c2009-0-64101-5 · Cited by 118
“Therefore, the well-documented effectiveness of psychostimulants in pediatric ADHD (Pliszka, 2007) could be explained by their vigilance stabilizing property.”
BackgroundBerger, I., Dor, T., Nevo, Y., & Goldzweig, G. (2008) · Journal of Child Neurology · doi:10.1177/0883073808317726 · Cited by 88
Personality Characteristics Associated with Persistent ADHD in Late Adolescence
Miller, C. J., Miller, S. R., Newcorn, J. H., & Halperin, J. M. (2007) · Research on Child and Adolescent Psychopathology · doi:10.1007/s10802-007-9167-7 · Cited by 99
Ito, H., Nagano, M., Suzuki, H., & Murakoshi, T. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.12.011 · Cited by 89
Knopf, H., Hölling, H., Huss, M., & Schlack, R. (2012) · BMJ Open · doi:10.1136/bmjopen-2011-000477 · Cited by 67
Blader, J. C., Pliszka, S. R., Kafantaris, V., Foley, C. A., Crowell, J. A., Carlson, G. A., Sauder, C. L., Margulies, D. M., Sinha, C., Sverd, J., et al. (2013) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.08.024 · Cited by 79
Self-citationSander, C., Arns, M., Olbrich, S., & Hegerl, U. (2010) · Clinical Neurophysiology · doi:10.1016/j.clinph.2010.03.021 · Cited by 69
“In the latter case, psychostimulants are considered the first line approach (Plizska, 2007; Soileau, 2008).”
Differences in feedback- and inhibition-related neural activity in adult ADHD
Dibbets, P., Evers, E. A. T., Hurks, P. P. M., Marchetta, N. D. J., & Jolles, J. (2009) · Brain and Cognition · doi:10.1016/j.bandc.2009.01.001 · Cited by 69
Woolley, M. L., Waters, K. A., Reavill, C., Bull, S., Lacroix, L. P., Martyn, A., Hutcheson, D. M., Valerio, E., Bate, S. T., Jones, D. N. C., et al. (2008) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32831c3b06 · Cited by 65
“…(Volkow et al., 1998; Spencer et al., 2006), and thereby increase extrasynaptic dopamine levels (Volkow et al., 2002, 2003), these psychostimulants are also associated with unwanted side effects such as insomnia, anorexia, headache, stomach problems and potential drug abuse (Pliszka, 2007).”
BackgroundAcute atomoxetine effects on the EEG of children with Attention-Deficit/Hyperactivity Disorder
Barry, R. J., Clarke, A. R., Hajós, M., McCarthy, R., Selikowitz, M., & Bruggemann, J. M. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.08.003 · Cited by 66
The Effect of Physical Activity on Children With ADHD: A Quantitative Review of the Literature
Cornelius, C., Fedewa, A. L., & Ahn, S. (2017) · Journal of Applied School Psychology · doi:10.1080/15377903.2016.1265622 · Cited by 74
“Furthermore, even after a second stimulant is tried, up to 20% of youth may still not successfully respond (Greenhill, Pliszka, & Duncan, 2002; Pliszka, 2007; Smith & Shapiro, 2015).”
BackgroundLeffa, D. T., Panzenhagen, A. C., Salvi, A. A., Bau, C. H. D., Pires, G. N., Torres, I. L. D. S., Rohde, L. A., Rovaris, D. L., & Grevet, E. H. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.02.019 · Cited by 54
“Despite some heterogeneity in response to MPH treatment (Wilens et al., 2011), there is a huge response rate to the drug, which is around 80% for both children and adults (Pliszka, 2007).”
BackgroundNeuropharmacological Mechanisms Underlying the Neuroprotective Effects of Methylphenidate
Volz, T. (2008) · Current Neuropharmacology · doi:10.2174/157015908787386041 · Cited by 46
Wehmeier, P. M., Dittmann, R., & Banaschewski, T. (2014) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-014-0156-8 · Cited by 53
Neurophysiological Correlates of Attentional Fluctuation in Attention-Deficit/Hyperactivity Disorder
Cheung, C. H. M., McLoughlin, G., Brandeis, D., Banaschewski, T., Asherson, P., & Kuntsi, J. (2017) · Brain Topography · doi:10.1007/s10548-017-0554-2 · Cited by 45
“2009; Pliszka 2007), limited research has investigated whether P3 amplitudes can be altered using non-pharmacological techniques.”
BackgroundTreatment of Acute Mania with Modafinil Monotherapy
Schoenknecht, P., Olbrich, S., Sander, C., Spindler, P., & Hegerl, U. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.12.021 · Cited by 42
Schecklmann, M., Ehlis, A.-C., Plichta, M. M., Dresler, T., Heine, M., Boreatti-Hümmer, A., Romanos, M., Jacob, C., Pauli, P., & Fallgatter, A. J. (2013) · Journal of Attention Disorders · doi:10.1177/1087054711429702 · Cited by 42
“Three patients took antidepressant medication, and 6 patients were treated with methylphenidate (MPH) that was discontinued at least 1 day prior to the measurement (equaling more than five half-life periods of MPH; Pliszka, 2007).”
BackgroundBush, G., Holmes, J., Shin, L. M., Surman, C., Makris, N., Mick, E., Seidman, L. J., & Biederman, J. (2013) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2012.09.004 · Cited by 41
“While a few studies have provided insights (Arnsten, 2006; Seneca et al., 2006; Logan et al., 2007; Pliszka, 2007; Chamberlain et al., 2009; Takano et al., 2009), the neural mechanisms by which ATMX exerts therapeutic effects remain unresolved.”
Enhancing neural markers of attention in children with ADHD using a digital therapeutic
Gallen, C. L., Anguera, J. A., Gerdes, M. R., Simon, A. J., Cañadas, E., & Marco, E. J. (2021) · PLoS ONE · doi:10.1371/journal.pone.0261981 · Cited by 48
“For example, pharmacological treatments often induce side effects such as reduced appetite [10] and there are barriers to obtaining non-pharmacological (behavioral) interventions [11, 12].”
BackgroundFrölich, J., Banaschewski, T., Döpfner, M., & Görtz‐Dorten, A. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.922542 · Cited by 42
“The response rate is 70 -- 85% [86-88] with normalization rates of the core symptoms of ~ 40 -- 50% [4,89,90].”
BackgroundSkoglund, C. B., Brandt, L., D'Onofrio, B. M., Larsson, H., & Franck, J. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.08.435 · Cited by 44
“Methylphenidate is the most commonly used stimulant medication (NICE guidelines 2008, Kooij et al., 2010) with an expected treatment response observed in about 80% of the patients (Pliszka, 2007).”
BackgroundChoi, E., Yoon, E.-H., & Park, M.-H. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.986687 · Cited by 43
Xie, K., Ge, S., Collins, V. E., Haynes, C. L., Renner, K. J., Meisel, R. L., Luján, R., & Martemyanov, K. A. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2409-y · Cited by 38
“G protein-coupled receptors .”
Pharmacotherapy for Attention-Deficit/Hyperactivity Disorder: From Cells to Circuits
Minzenberg, M. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0128-7 · Cited by 40
“Clinical considerations in the use of these medications (such as pharmacokinetics, efficacy, adverse events, guidelines for use, and so forth) are also reviewed in numerous publications elsewhere [35–41].”
BackgroundOsokogu, O. U., Fregonese, F., Ferrajolo, C., Verhamme, K., de Bie, S., Jong, G. ’., Catapano, M., Weibel, D., Kaguelidou, F., Bramer, W. M., et al. (2015) · Drug Safety · doi:10.1007/s40264-015-0265-0 · Cited by 31
“…anemia [41]; quinine–agranulocytosis [42]; quinine–thrombocytopenia [43]; isotretinoin–psychosis [44, 45]; methylphenidate– psychosis [46, 47]; isotretinion–suicide [44, 45]; dom-peridone–ventricular arrhythmia [48]; domperidone–sudden death [49]; clarithromycin–QT prolongation [50];…”
Macphee, F. L., Merrill, B. M., Altszuler, A. R., Ramos, M. C., Gnagy, E. M., Greiner, A. R., Coxe, S., Raiker, J. S., Coles, E., Burger, L., et al. (2019) · School Psychology Review · doi:10.17105/spr-2017-0151.v48-3 · Cited by 12
“This was based on the longstanding literature suggesting that psychostimulants consistently produce acute and large ameliorative effects on ADHD symptoms and related disruptive behavior for most children with ADHD (Faraone & Buitelaar, 2010; Pelham et al., 2001; Pliszka, 2007).”
BackgroundCannabis use in Attention – Deficit/Hyperactivity Disorder (ADHD): A scoping review
Francisco, A. P., Lethbridge, G., Patterson, B. A., Bergmann, C. G., & Ameringen, M. V. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.11.029 · Cited by 34
Sterley, T.-L., Howells, F. M., & Russell, V. A. (2012) · Brain Research · doi:10.1016/j.brainres.2012.12.029 · Cited by 37
“Furthermore, treatments, such as atomoxetine, a NET blocker, and guanfacine and clonidine, a2-adrenoceptor agonists, have been found to be effective in alleviating behavioural symptoms of ADHD in patients (Arnsten et al., 2007; Chamberlain et al., 2007; Pliszka, 2007).”
Larrañaga-Fragoso, P., Noval, S., Rivero, J. C., & Bueis, A. B. D. L. (2015) · Journal of American Association for Pediatric Ophthalmology and Strabismus · doi:10.1016/j.jaapos.2015.04.005 · Cited by 33
Multimodal treatment for childhood attention-deficit/hyperactivity disorder
Kaiser, N. M., Hoza, B., & Hurt, E. A. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.10.1573 · Cited by 31
Medication and creativity in Attention Deficit Hyperactivity Disorder (ADHD)
Hernández, G. G.-C., & Selva, J. S. (2016) · Psicothema · doi:10.7334/psicothema2015.126 · Cited by 40
Todor, I., Popa, A., Neag, M. A., Muntean, D. M., Bocșan, I. C., Buzoianu, A. D., Vlase, L., Gheldiu, A.-M., & Briciu, C. (2016) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3h03r · Cited by 30
Azami, S., Moghaddas, A., Sohrābi, F., Nazifi, M., Mirmohammad, M. S., Hemmati, F., Ahmadi, A., Hamzeh‐poor, P., Khari, S., & Lakes, K. D. (2016) · Child and Adolescent Mental Health · doi:10.1111/camh.12157 · Cited by 29
Işık, Ü., & Kaygisiz, M. (2020) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2019-0606 · Cited by 26
EEG Vigilance and Phenotypes in Neuropsychiatry
Arns, M., Gunkelman, J. D., Olbrich, S., Sander, C., & Hegerl, U. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-382235-2.00004-4 · Cited by 30
Chiarenza, G. A., Chabot, R. J., Isenhart, R., Montaldi, L., Chiarenza, M. P., Torto, M. G. L., & Prichep, L. S. (2016) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2016.04.004 · Cited by 26
ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN, ADOLESCENTS, AND ADULTS
Schachar, R. J. (2009) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000348879.09070.21 · Cited by 26
He, J. A., & Antshel, K. M. (2016) · Cognitive and Behavioral Practice · doi:10.1016/j.cbpra.2016.03.010 · Cited by 32
Kirkland, A. E., & Holton, K. F. (2019) · Clinical EEG and Neuroscience · doi:10.1177/1550059418817966 · Cited by 24
Exocytosis-related genes and response to methylphenidate treatment in adults with ADHD
da Silva, B. S., Cupertino, R. B., Rovaris, D. L., Schuch, J. B., Kappel, D. B., Müller, D., Bandeira, C. E., Victor, M. M., Karam, R. G., Mota, N. R., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.90 · Cited by 24
Epstein, J. N., Kelleher, K. J., Baum, R., Brinkman, W. B., Peugh, J., Gardner, W. P., Lichtenstein, P., & Langberg, J. M. (2017) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2017.03.014 · Cited by 19
Quantitative EEG in Childhood Attention Deficit Hyperactivity Disorder and Learning Disabilities
Chiarenza, G. A. (2020) · Clinical EEG and Neuroscience · doi:10.1177/1550059420962343 · Cited by 24
Creativity in Children with Attention Déficit Hyperactivity Disorder (ADHD)
Hernández, G. G.-C., Serrano, J. P., & Nieto, M. (2017) · Psychology · doi:10.4236/psych.2017.83019 · Cited by 71
Resilience in Childhood Disorders
Climie, E. A., Mastoras, S. M., McCrimmon, A. W., & Schwean, V. L. (2012) · Plenum series on human exceptionality · doi:10.1007/978-1-4614-4939-3_8 · Cited by 26
Ist manisches Verhalten ein autoregulatorischer Versuch zur Vigilanzstabilisierung?
Hegerl, U., Olbrich, S., Schönknecht, P., & Sander, C. (2008) · Der Nervenarzt · doi:10.1007/s00115-008-2553-8 · Cited by 19
Miranda, P., Cox, C. D., Alexander, M., Danev, S., & Lakey, J. R. T. (2020) · Medical Devices Evidence and Research · doi:10.2147/mder.s241205 · Cited by 24
Warrer, P., Thomsen, P. H., Dalsgaard, S., Hansen, E. H., Aagaard, L., Wallach‐Kildemoes, H., & Rasmussen, H. B. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0060 · Cited by 15
“…disorder (ADHD) in children and adolescents (National Institute for Health and Care Excellence 2006, 2013), with stimulants such as methylphenidate (MPH) and amphetamines being the most widely prescribed medicines worldwide (Pliszka 2007; Findling 2008; Wigal 2009; Dalsgaard et al. 2013).”
BackgroundPujalte, G. G. A., Narducci, D. M., Smith, M. S., King, R. L., Logan, K., Callender, S. S., Liebman, C., Kane, S. F., Israel, M., Wolf, S. F., et al. (2023) · Clinical Journal of Sport Medicine · doi:10.1097/jsm.0000000000001152 · Cited by 20
“Stimulants remain first-line medications; nonstimulant medications may be considered when stimulants fail, are poorly tolerated, or are contraindicated.(64,65) Stimulants for ADHD treatment includemethylphenidate, dextroamphetamineamphetamine salts, modafinil, and dextroamphetamine;most are available in short- and lon…”
BackgroundArvidsson, M., Dahl, M., Beck, O., Ackehed, G., Nordin, K., & Rosenborg, S. (2019) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-019-02787-x · Cited by 16
“The first-line pharmacological treatment for ADHD is stimulant medications, either methylphenidate (MPH) or amphetamine [3].”
BackgroundThe Pharmacokinetics and Pharmacogenomics of Psychostimulants
Markowitz, J. S., & Melchert, P. W. (2022) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2022.03.003 · Cited by 18
Sterley, T.-L., Howells, F. M., & Russell, V. A. (2014) · Brain Research · doi:10.1016/j.brainres.2014.05.005 · Cited by 16
“Drugs used to treat behavioural symptoms of ADHD serve to increase extracellular levels of norepinephrine in the brain (Pliszka, 2007; Arnsten, 2010).”
Janols, L., Liliemark, J. O., Klintberg, K., & von Knorring, A. (2009) · Nordic Journal of Psychiatry · doi:10.3109/08039480903154534 · Cited by 17
Moore, K. P., Wb, D., Reaney, J. B., Crandell, M., & Huxsahl, J. E. (2007) · Cited by 19
Merrill, B. M., Raiker, J. S., Mattfeld, A. T., Macphee, F. L., Ramos, M. C., Zhao, X., Altszuler, A. R., Schooler, J. W., Coxe, S. J., Gnagy, E. M., et al. (2022) · Research on Child and Adolescent Psychopathology · doi:10.1007/s10802-022-00912-6 · Cited by 17
“Herein, MPH improved attentional performance (i.e., RTV) and classroom productivity, confirming hypotheses and replicating decades of research supporting stimulant efficacy (Pliszka, 2007).”
BackgroundInfluentialIs there a place for dietetic interventions in adult ADHD?
Breda, V., Cerqueira, R. O., Ceolin, G., Koning, E., Fabe, J., McDonald, A., Gomes, F. A., & Brietzke, E. M. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110613 · Cited by 25
Sobanski, E., Leppämäki, S., Bushe, C., Berggren, L., Casillas, M., & Deberdt, W. G. (2015) · European Psychiatry · doi:10.1016/j.eurpsy.2015.09.005 · Cited by 13
“Currently recommended pharmacotherapies for ADHD in adults include stimulants such as methylphenidate and amphetamines, and the non-stimulant medication atomoxetine [15,28,35,36].”
BackgroundCorona, R., Dvorsky, M. R., Romo, S., Parks, A. M., Bourchtein, E., Smith, Z. R., Avila, M., & Langberg, J. M. (2020) · Research on Child and Adolescent Psychopathology · doi:10.1007/s10802-020-00689-6 · Cited by 15
“Pharmacological treatment, the most common treatment for ADHD (Visser et al. 2014), can produce marked improvement in ADHD symptoms (Pliszka 2007), but these improvements often do not translate into reductions in tobacco use.”
BackgroundCurrent issues and trends in the diagnosis and treatment of adults with ADHD
Cumyn, L., Kolar, D., Keller, A., & Hechtman, L. T. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.10.1375 · Cited by 19
Jain, R., & Stark, J. G. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1218259 · Cited by 13
“toms of ADHD, with improvement noted for 65–75% of patients in all age groups [37,38].”
BackgroundThe American Psychiatric Association Publishing Textbook of Psychiatry
Roberts, L. W. (2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372980 · Cited by 34
Goetz, M., Yeh, C., Ondrejka, I., Akay, A. P., Herczeg, I., Dobrescu, I., Kim, B., Jin, X., Riley, A. W., Martényi, F., et al. (2010) · Journal of Attention Disorders · doi:10.1177/1087054710381480 · Cited by 13
“Treatments also include nonconventional interventions such as alternative or complementary medicines and homeopathy (Goldman et al., 1998; Pliszka, 2007; Swanson et al., 1998).”
BackgroundSchlander, M., Trott, G.-E., & Schwarz, O. (2009) · Der Nervenarzt · doi:10.1007/s00115-009-2889-8 · Cited by 18
Evidence-based Psychosocial Treatments for Childhood ADHD
Kaiser, N. M., & Pfiffner, L. J. (2011) · Psychiatric Annals · doi:10.3928/00485713-20101221-03 · Cited by 20
Montoya, A., Escobar, R., García-Polavieja, M. J., Lachno, D. R., Alda, J. A., Artigas-Pallarés, J., Cardo, E., Giral, M. G., Gastaminza, X., & Gilaberte, I. (2010) · Journal of Child Neurology · doi:10.1177/0883073810371981 · Cited by 11
“The efficacy of drug treatments is determined by their ability to restore appropriate responses by these systems.(3,8) In this vein, previous investigations have reported an association of cognitive performance and other neuropsychological outcomes with plasma and urine levels of norepinephrine and dopamine metabolite…”
BackgroundLynch, J. J., Regan, C. P., Stump, G. L., Tannenbaum, P. L., Stevens, J., Bone, A., Gilberto, D. B., Johnson, C. A., Fujino, N., Takenaga, N., et al. (2009) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318195a470 · Cited by 10
Kızıltunç, P. B., Yürümez, E., & Atilla, H. (2022) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_2966_21 · Cited by 11
“Headache, appetite loss, and insomnia are the most common side effects.[3] This drug has also some ocular side effects including dry eyes, blurred vision, pupil dilatation, and accommodation disorders.”
BackgroundPrescription and Over-the-Counter Medications
Eaddy, J. L. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-398336-7.00076-0 · Cited by 12
Avisar, A., & Lavie‐Ajayi, M. (2014) · Ethical Human Psychology and Psychiatry · doi:10.1891/1559-4343.16.1.37 · Cited by 19
“In addition, the literature discusses negative side effects of these medications, but references almost always point to headaches, stomachaches, sleeping problems, and loss of appetite (e.g., Goldman, Genel, Bezman,& Slantez, 1998; Pliszka, 2007; Wilens et al., 2006; Wolraich et al., 2001).”
BackgroundBordoff, B. (2017) · Psychological Injury and Law · doi:10.1007/s12207-017-9288-4 · Cited by 15
Long-term Safety of Stimulant Medications Used to Treat Children with ADHD
Gilchrist, R. H., & Arnold, L. E. (2008) · Pediatric Annals · doi:10.3928/00904481-20080101-05 · Cited by 10
Attention-Deficit Hyperactivity Disorder
Sinha, J. K., Durgvanshi, S., & Ghosh, S. (2022) · Springer eBooks · doi:10.1007/978-3-319-55065-7_1057 · Cited by 10
Martényi, F., Zheng, Y., Huang, Y., Lee, Y. S., Walton, R., Harrison, G. L., & Treuer, T. (2010) · PubMed · Cited by 9
Sluggish Cognitive Tempo: realidades y controversias
Baleares, U. D. L. I., Bernad, M. D. M., Servera, M., & Baleares, U. D. L. I. (2016) · Revista Mexicana de Investigación en Psicología · doi:10.32870/rmip.vi.572 · Cited by 10
“…y filtración de información sensorial, mientras que aquellos con TDAH clásico tienen problemas con la inhibición (Capdevila-Borphy et al., 2006) o bien aparentan energía excesiva sin dificultades en el procesamiento de la información (Barkley, 2009; Martín-González et al. 2008; Pliszka, 2007).”
Gripped by the chaos: a psychoanalytically-informed qualitative exploration of adolescent ADHD
Clancy, J., O’Connor, J., & Mhaoláin, C. N. (2020) · Psychoanalytic Psychotherapy · doi:10.1080/02668734.2020.1854834 · Cited by 6
Fu, D., Guo, H., Hu, Y., Fang, W., Liu, Q., Xu, J., Wu, D., & Chen, F. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-022-03449-1 · Cited by 12
“In the case of comorbid ADHD and major depressive disorder, some guidelines recommend the add-on of an antidepressant with atomoxetine [151].”
BackgroundPsychopharmaka im Kindes- und Jugendalter
Libal, G., & Schmeck, K. (2009) · Therapeutische Umschau · doi:10.1024/0040-5930.66.6.467 · Cited by 7
“Da für beide Medikamente auch eine Wirksamkeit bei Tics beschrieben ist, kann vor allem bei ADHSPatienten mit komorbiden Tics an einen Einsatz gedacht werden [9, 14].”
BackgroundEffects of Omega-3 Fatty Acids on Cognition and Behaviour in Childhood
Thornberg, U. B. (2011) · Cited by 6
THE INFLUENCE OF PAROXETINE ON THE PHARMACOKINETICS OF ATOMOXETINE AND ITS MAIN METABOLITE
Todor, I., Popa, A., Neag, M. A., Muntean, D. M., Bocșan, I. C., Buzoianu, A. D., Vlase, L., Gheldiu, A.-M., Chira, R., & Briciu, C. (2015) · Medicine and Pharmacy Reports · doi:10.15386/cjmed-488 · Cited by 7
“Serotonin reuptake inhibitors can also be added to ADHD therapy for patients with ADHD and comorbid anxiety [20].”
BackgroundStimulants for Treating Bipolar Disorder
Grunze, H. (2014) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000003 · Cited by 6
“In line with these findings, the seemingly paradoxical therapeutic effects of psychostimulants in ADHDmight be related to their vigilance-enhancing properties.(43) To the author’s knowledge, however, no direct correlation of central nervous system dopaminergic activity in relation to vigilance as measured by EEG has b…”
ResultADHS im Kindes- und Jugendalter. Update 2020
Popow, C., & Ohmann, S. (2020) · Pädiatrie & Pädologie · doi:10.1007/s00608-020-00789-y · Cited by 8
Fu, Z., Tian, J., Kang, S., Qin, Z., Cao, Q., Wang, Y., Deng, J., & Yang, L. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03407-0 · Cited by 7
Zahed, G., Roozbakhsh, M., Ashtiani, R. D., & Razjouyan, K. (2022) · Iranian journal of child neurology. · doi:10.22037/ijcn.v16i2.32541 · Cited by 8
“Multiple studies have shown the efficacy of modafinil in improving attention and reducing the impulsivity of children with ADHD (34, 35, 36, 37, 38, 39).”
BackgroundAttention Deficit Hyperactivity Disorder: Part III
Ryan‐Krause, P. (2010) · Journal of Pediatric Health Care · doi:10.1016/j.pedhc.2010.10.001 · Cited by 6
“In addition, loss of appetite occasionally severe enough to cause concern about weight loss can be seen (Pliszka, 2007).”
BackgroundMehrjerdi, Z. A., Noroozi, A., Barr, A. M., & Ekhtiari, H. (2012) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 5
Metadata
- Authors
- Pliszka, S. R.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Corresponding author
- Pliszka, Steven R.
- ORCID
- Pliszka, Steven R.
- Venue
- Neuropsychology Review
- Published
- 2007-01-23
- Volume
- 17
- Issue
- 1
- Pages
- 61-72
- ISSN
- 1040-7308 (ISSN-L)
- 1573-6660
- OpenAlex
- W2081088104
- Cited by
- 158
- References
- 99
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 3 · 2023: 4 · 2022: 9 · 2021: 3 · 2020: 10 · 2019: 11 · 2018: 2 · 2017: 13 · 2016: 10 · 2015: 7 · 2014: 12 · 2013: 5 · 2012: 12
- FWCI
- 1.92
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychology Review (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Social Sciences › Psychology › Neuropsychology and Physiological Psychology › Developmental and Educational Neuropsychology
- Keywords
- attention deficit hyperactivity disorder, pharmacotherapy, long-acting stimulants, atomoxetine, drug efficacy, drug safety, adverse effects, sudden death risk, mechanism of action, catecholamines, prefrontal cortex, anterior cingulate cortex, neuroimaging
- MeSH terms
- Atomoxetine Hydrochloride, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Decision Trees, Humans, Propylamines, Neurotransmitter Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.